Schonfeld Strategic Advisors LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$4,078,800
+478.6%
220,000
+335.6%
0.03%
+433.3%
Q3 2022$705,000
+94.2%
50,503
+126.5%
0.01%
+100.0%
Q1 2022$363,000
-76.3%
22,300
-76.3%
0.00%
-78.6%
Q4 2021$1,534,000
+21.2%
94,164
+10.4%
0.01%
+7.7%
Q3 2021$1,266,000
+429.7%
85,264
+1380.8%
0.01%
+160.0%
Q3 2020$239,000
-85.1%
5,758
-82.8%
0.01%
-76.2%
Q2 2020$1,600,000
+140.2%
33,390
+521.2%
0.02%
+31.2%
Q4 2019$666,000
-68.8%
5,375
-83.3%
0.02%
-74.6%
Q3 2019$2,137,000
+194.4%
32,200
-21.0%
0.06%
-4.5%
Q3 2017$726,000
-40.0%
40,738
+265.9%
0.07%
-58.0%
Q4 2016$1,209,00011,1340.16%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders